Exelixis, Inc. (EXEL) stock
EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
Financials through Q3 FY2026, quarter ended Oct 2, 2026Last filing: 10-Q on Oct 29, 2026Score 18/301% above fair value
$67.10−1.90 (-2.75%)
Close on Nov 16, 2026Market cap $16.37BP/E 20.1Yield –
Exelixis profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Exelixis's profit margin for the twelve months ending Oct 2, 2026 was 35.5%. For fiscal 2025 it was 33.7%, against 24.0% the year before. The highest annual figure on record is 80.8% in fiscal 2018.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | 33.7% | +9.7 |
| FY2024 | Jan 3, 2025 | 24.0% | +12.7 |
| FY2023 | Dec 29, 2023 | 11.4% | +0.0 |
| FY2022 | Dec 30, 2022 | 11.3% | −4.8 |
| FY2021 | Dec 31, 2021 | 16.1% | +4.8 |
| FY2020 | Jan 1, 2021 | 11.3% | −21.9 |
| FY2019 | Jan 3, 2020 | 33.2% | −47.7 |
| FY2018 | Dec 28, 2018 | 80.8% | +46.7 |
| FY2017 | Dec 29, 2017 | 34.1% | +70.8 |
| FY2016 | Dec 31, 2016 | -36.7% | +398.4 |
| FY2015 | Dec 31, 2015 | -435.1% | +605.4 |
| FY2014 | Dec 31, 2014 | -1040.6% | −280.5 |
| FY2013 | Dec 31, 2013 | -760.1% | −453.8 |
| FY2012 | Dec 31, 2012 | -306.3% | −332.4 |
| FY2011 | Dec 31, 2011 | 26.1% | +76.0 |
| FY2010 | Dec 31, 2010 | -49.9% | +39.2 |
| FY2009 | Dec 31, 2009 | -89.1% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Oct 2, 2026 | 33.1% | +0.7 |
| Q2 FY2026 | Jul 3, 2026 | 33.7% | +1.2 |
| Q1 FY2026 | Apr 3, 2026 | 34.5% | +5.7 |
| Q4 FY2025 | Jan 2, 2026 | 40.8% | +16.2 |
| Q3 FY2025 | Oct 3, 2025 | 32.4% | +10.5 |
| Q2 FY2025 | Jul 4, 2025 | 32.5% | −3.0 |
| Q1 FY2025 | Apr 4, 2025 | 28.7% | +20.0 |
| Q4 FY2024 | Jan 3, 2025 | 24.7% | +6.8 |
| Q3 FY2024 | Sep 27, 2024 | 21.9% | +21.6 |
| Q2 FY2024 | Jun 28, 2024 | 35.5% | +18.2 |
| Q1 FY2024 | Mar 29, 2024 | 8.8% | −1.0 |
| Q4 FY2023 | Dec 29, 2023 | 17.8% | +24.9 |
| Q3 FY2023 | Sep 29, 2023 | 0.2% | −17.6 |
| Q2 FY2023 | Jun 30, 2023 | 17.3% | +0.4 |
| Q1 FY2023 | Mar 31, 2023 | 9.8% | −9.5 |
| Q4 FY2022 | Dec 30, 2022 | -7.1% | −28.2 |
| Q3 FY2022 | Sep 30, 2022 | 17.8% | +6.1 |
| Q2 FY2022 | Jul 1, 2022 | 16.8% | −8.1 |
| Q1 FY2022 | Apr 1, 2022 | 19.3% | +18.7 |
| Q4 FY2021 | Dec 31, 2021 | 21.1% | +10.6 |
| Q3 FY2021 | Oct 1, 2021 | 11.6% | +25.5 |
| Q2 FY2021 | Jul 2, 2021 | 24.9% | −0.8 |
| Q1 FY2021 | Apr 2, 2021 | 0.6% | −20.8 |
| Q4 FY2020 | Jan 1, 2021 | 10.5% | −18.1 |
| Q3 FY2020 | Oct 2, 2020 | -13.9% | −49.7 |
| Q2 FY2020 | Jul 3, 2020 | 25.8% | −7.1 |
| Q1 FY2020 | Apr 3, 2020 | 21.4% | −13.7 |
| Q4 FY2019 | Jan 3, 2020 | 28.6% | −128.9 |
| Q3 FY2019 | Sep 27, 2019 | 35.9% | −20.3 |
| Q2 FY2019 | Jun 28, 2019 | 32.9% | −14.1 |
| Q1 FY2019 | Mar 29, 2019 | 35.2% | −19.0 |
| Q4 FY2018 | Dec 28, 2018 | 157.5% | +125.5 |
| Q3 FY2018 | Sep 28, 2018 | 56.2% | +2.8 |
| Q2 FY2018 | Jun 29, 2018 | 47.0% | +29.2 |
| Q1 FY2018 | Mar 30, 2018 | 54.2% | +33.6 |
| Q4 FY2017 | Dec 29, 2017 | 32.1% | −13.2 |
| Q3 FY2017 | Sep 30, 2017 | 53.4% | – |
| Q2 FY2017 | Jun 30, 2017 | 17.8% | – |
| Q1 FY2017 | Mar 31, 2017 | 20.6% | – |
| Q4 FY2016 | Dec 31, 2016 | 45.3% | – |
See a number that looks wrong?